Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 58130-nm albumin-bound paclitaxel 36Specimen Handling 27Magnetic Resonance Spectroscopy 22Albumin-Bound Paclitaxel 22Fluorouracil 20Leucovorin 19Irinotecan 19Biopsy 18Taxes 17Oxaliplatin 17pembrolizumab 14Cisplatin 12Cyclophosphamide 11fludarabine 10Cetuximab 9Nivolumab 8Carboplatin 8Capecitabine 8Pemetrexed 7irinotecan sucrosofate 6durvalumab 6dehydroftorafur 6Radiosurgery 6olaparib 5Ipilimumab 5Erlotinib Hydrochloride 5Blood Specimen Collection 5trastuzumab deruxtecan 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Biopsy, Needle × 90 days × Clear all
NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡